Follow Stryker to never miss an important update.
Stryker is moving through a planned leadership change. Kevin Lobo will step down as CEO at the end of 2026 and transition to the role of Executive Chair. Spencer Stiles, who has been with the company for 27 years and currently serves as President and Chief Operating Officer, will take the top job.
This looks like an orderly succession rather than a sudden shift. Mr. Stiles has deep experience across the company's main divisions, including the orthopaedics business that houses its important Mako robotic systems. Because he is an internal veteran who already helps run the day-to-day business, the company's strategy is unlikely to see a major pivot. For long-term owners, the focus remains on whether the company can keep placing more robots in hospitals to drive steady sales of its surgical implants.
Source: 8-K filing
Stryker's finance chief recently shared that a manufacturing issue within its peripheral vascular unit, which makes tools to treat narrowed blood vessels, is still ongoing. The company had previously suggested this problem was resolved, making this update a setback for a division that has been under scrutiny.
While this specific business is smaller than Stryker's core joint-replacement arm, these kinds of lingering production flaws can lead to higher costs or lost sales if hospitals switch to rivals. For long-term owners, the concern is whether this indicates a deeper struggle with quality control or if it is simply a localized hurdle that will take a few more months to clear.
Source: GlobeNewsWire
Stryker received regulatory clearance for SportSuite Vision, the first app designed for use inside an operating room with Apple's headset. The technology allows surgeons to view digital patient data and surgical plans in their line of sight while they work, rather than having to look away at a separate monitor.
This launch is a move to keep Stryker at the center of the modern operating room. By building software that works with high-end hardware like the Vision Pro, the company makes its surgical tools more useful and harder for hospitals to replace with a rival's system.
Source: PRNewsWire
Stryker is buying ZuriMED, a private firm that developed the FiberLocker System. This technology helps secure tendons during shoulder surgery, addressing a common problem where repairs can pull apart or fail during healing. While this is a small acquisition, it fits Stryker's strategy of buying niche technologies to fill gaps in its massive catalog. Adding specialized tools for shoulder repair helps the company win more business from orthopedic surgeons who already use its other joint replacement products.
Source: GlobeNewsWire
Wolfe Research downgraded the medical technology company to Peer Perform, which is their way of saying they expect the stock to perform in line with its rivals rather than beating them. This change comes as the stock sits at about $335, well below the average analyst target of $383.
While the company remains a leader in robotic-assisted surgery, a downgrade like this often suggests analysts see fewer reasons for the stock to rise in the near term. For long-term owners, the core of the business still relies on hospitals continuing to buy its surgical robots and the specific implants that go with them.
Stryker consistently clears the bar with small, reliable beats, showing that management has a tight grip on the business and sets targets they know they can hit.
| Expectation | |
|---|---|
| EPS | $3.56 |
| Revenue | $6.63B |